Tag:
Molnupiravir
Bedford, NY
Business
Covid-
19: Stop & Shop Pharmacies Now Offering Anti-Viral Medication
Stop & Shop has begun offering two approved COVID-19 antiviral medicines, Pfizer's Paxlovid and Merck's Molnupiravir at its 55 New York pharmacies. The mega-supermarket chain made the announcement on Thursday, April 7, that the drugs would be available at no cost with a valid prescription from a health care provider. The COVID-19 anti-viral medication Molnupiravir can be prescribed to those 18 and older, while Paxlovid is authorized for use by adults and children ages 12 and older weighing at least 88 pounds, store officials said. Availability of the anti-viral oral prescript…
White Plains, NY
News
Covid-
19: FDA Authorizes Second Antiviral Pill
For the second time in as many days, the Food and Drug Administration (FDA) has authorized the use of an antiviral pill to treat mild and moderate COVID-19 cases. On Thursday, Dec. 23, the FDA approved the use of Merck’s molnupiravir pill for emergency use authorization, a day after officials authorized the use of Pfizer’s COVID-19 treatment pill. Earlier story - COVID-19: FDA OKs First Authorized Home Treatment For Virus Merck’s pill has been cleared for use by adults 18 and older who have tested positive for COVID-19 and are at the greatest risk of being hospitalized or dying from t…
Elizabeth, NJ
News
NJ Company's Experimental COVID Drug Could Be Major Game-Changer
New Jersey drug manufacturer Merck & Co. and Ridgeback Biotherapeutics on Friday said the new experimental COVID-19 drug significantly reduces hospitalization time and chance of death for 50 percent of patients with mild to moderate cases. In light of the new findings, the Kenilworth-based company has stopped the drug's trial to apply for emergency use authorization. Molnupiravir is an oral pill and inhibits the replication of the virus inside of the body. “The news of the efficacy of this particular antiviral is obviously very good news,” White House chief medical advisor Dr. Ant…
Pleasantville, NY
News
Covid-
19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus
A new pharmaceutical company is throwing its hat in the ring as the country continues its fight against COVID-19. Merck and Ridgeback Biotherapeutics announced on Friday, Oct. 1 that it is planning to apply for federal emergency approval of a pill that can reportedly help prevent hospitalizations and deaths in COVID-19 patients. According to the company, trials have found that the pill - dubbed molnupiravir - could potentially reduce the risk of hospitalization or death in patients with mild to moderate COVID-19 by approximately 50 percent. The results of the late-stage trial have bee…
Stamford, CT
Lifestyle
Covid-
19: Little Brown Pill Could Be Difference Maker In Fight Against Virus
Scientists may have cracked the code to help in the fight against COVID-19 and potential future pandemics. Though still in clinical trials, the “little brown pill” molnupiravir may give doctors and researchers a new tool and treatment as the country continues combating the latest wave of COVID-19 cases. Merck (also known as MSD), and Ridgeback Biotherapeutics, LP announced earlier this month that they ran a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy of the pill to eliminate the strain that causes COVID-19. According to the prelimin…
Edison, NJ
News
Covid-
19: NJ Drug Manufacturer Merck Says New Antiviral Drug Shows Quick Reduction In Virus
Experimental antiviral drug molnupiravir being developed by New Jersey drug manufacturer Merck with Ridgeback Bio shows a quick reduction of the infectious virus in a study among participants with early COVID-19. Molnupiravir is being tested in a Phase 2/3 trial set to be completed in May. Merck will be provided with up to $268.8 million in funding from the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services. Associate Professor of Medicine at the University of North Carolina School of Medicine William Fis…
